Co-expression of PD-L1 Antibodies Enhances the Anti-Tumor Efficacy of Chimeric Antigen Receptor T Cells

Shruti Lal, Guan Wang, Zhoushi Chen, X. Xiang, Chengyu Liang, Xue F. Huang, Si-Yi Chen
{"title":"Co-expression of PD-L1 Antibodies Enhances the Anti-Tumor Efficacy of Chimeric Antigen Receptor T Cells","authors":"Shruti Lal, Guan Wang, Zhoushi Chen, X. Xiang, Chengyu Liang, Xue F. Huang, Si-Yi Chen","doi":"10.35248/2684-1266.19.5.119","DOIUrl":null,"url":null,"abstract":"Chimeric antigen receptor T (CAR-T) cell therapy against solid tumors has shown limited success in clinical trials. Solid tumors with highly immunosuppressive tumor microenvironment limit the anti-tumor efficacy of CAR-T cell therapy. Herein we generated a novel vector that co-express human mesothelin (MSLN)-targeted CAR and secretory human anti-programmed death ligand 1 (PD-L1) antibodies. The anti-PD-L1 antibodies secreted from the transduced T cells were able to block the interaction of PD-1/PD-L1 to overcome PD-L1-mediated immune suppression. The CAR-T cells targeting mesothelin and secreting PD-L1 antibodies enhanced cytolytic activity against MSLN+PD-L1+ tumor cells and increased the production of cytokines IL-2, TNFα, and IFNγ. The CAR-T cells targeting MSLN and secreting PD-L1 antibodies had enhanced anti-tumor efficacy when compared with the MSLN-targeted CAR-T cells in xenograft mouse models of mesothelioma, pancreatic and ovarian cancers. The results of this study demonstrated that the co-expression of PD-L1 antibody enhances the anti-tumor efficacy of CAR-T cell therapy against solid tumors.","PeriodicalId":22619,"journal":{"name":"The Journal of Cancer Research","volume":"63 1","pages":"1-9"},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Cancer Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35248/2684-1266.19.5.119","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Chimeric antigen receptor T (CAR-T) cell therapy against solid tumors has shown limited success in clinical trials. Solid tumors with highly immunosuppressive tumor microenvironment limit the anti-tumor efficacy of CAR-T cell therapy. Herein we generated a novel vector that co-express human mesothelin (MSLN)-targeted CAR and secretory human anti-programmed death ligand 1 (PD-L1) antibodies. The anti-PD-L1 antibodies secreted from the transduced T cells were able to block the interaction of PD-1/PD-L1 to overcome PD-L1-mediated immune suppression. The CAR-T cells targeting mesothelin and secreting PD-L1 antibodies enhanced cytolytic activity against MSLN+PD-L1+ tumor cells and increased the production of cytokines IL-2, TNFα, and IFNγ. The CAR-T cells targeting MSLN and secreting PD-L1 antibodies had enhanced anti-tumor efficacy when compared with the MSLN-targeted CAR-T cells in xenograft mouse models of mesothelioma, pancreatic and ovarian cancers. The results of this study demonstrated that the co-expression of PD-L1 antibody enhances the anti-tumor efficacy of CAR-T cell therapy against solid tumors.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
PD-L1抗体的共表达增强了嵌合抗原受体T细胞的抗肿瘤作用
嵌合抗原受体T (CAR-T)细胞治疗实体瘤在临床试验中显示出有限的成功。具有高度免疫抑制肿瘤微环境的实体瘤限制了CAR-T细胞治疗的抗肿瘤效果。在这里,我们产生了一种新的载体,共表达人间皮素(MSLN)靶向CAR和分泌人抗程序性死亡配体1 (PD-L1)抗体。从转导的T细胞分泌的抗PD-L1抗体能够阻断PD-1/PD-L1的相互作用,克服PD-L1介导的免疫抑制。靶向间皮素并分泌PD-L1抗体的CAR-T细胞增强了对MSLN+PD-L1+肿瘤细胞的细胞溶解活性,并增加了细胞因子IL-2、TNFα和IFNγ的产生。与靶向MSLN的CAR-T细胞相比,靶向MSLN并分泌PD-L1抗体的CAR-T细胞在间皮瘤、胰腺癌和卵巢癌的异种移植小鼠模型中具有更强的抗肿瘤效果。本研究结果表明,PD-L1抗体的共表达增强了CAR-T细胞治疗实体瘤的抗肿瘤效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Assessment of alternative approaches of primary cervical cancer screening among women in low-income environments Impact of an Educational Program on Sexual Dysfunction Associated With Cervical Cancer Self-Knowledge among Women with Cervical Cancer Open the Therapeutic Revolution Door of Antiviral Antitumor by Improving Systemic Non-Specific Immunity A Case of Philadelphia Chromosome-Positive Acute Myeloid Leukemia (Ph+AML) of Primary Drug Resistance and Relevant Literature Review
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1